Pages that link to "Q42702220"

The following pages link to J Gerry Kenna (Q42702220):

Displaying 45 items.

• Key Challenges and Opportunities Associated with the Use of In Vitro Models to Detect Human DILI: Integrated Risk Assessment and Mitigation Plans (Q28075991) (← links)
• Mass spectrometric characterization of circulating covalent protein adducts derived from a drug acyl glucuronide metabolite: multiple albumin adductions in diclofenac patients (Q33944025) (← links)
• Differential effect of troglitazone on the human bile acid transporters, MRP2 and BSEP, in the PXB hepatic chimeric mouse. (Q34294773) (← links)
• Safety pharmacology--current and emerging concepts. (Q34754400) (← links)
• Cellular models for ADMET predictions and evaluation of drug-drug interactions. (Q35674856) (← links)
• Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. (Q36761687) (← links)
• Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibition (Q37279800) (← links)
• Cell based approaches for evaluation of drug-induced liver injury. (Q37580306) (← links)
• Managing the challenge of chemically reactive metabolites in drug development. (Q37860142) (← links)
• Systems biology tools for toxicology (Q38008573) (← links)
• Systems toxicology: modelling biomarkers of glutathione homeostasis and paracetamol metabolism (Q38606517) (← links)
• Human biology-based drug safety evaluation: scientific rationale, current status and future challenges. (Q38763000) (← links)
• Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists (Q38932901) (← links)
• Fabrication and evaluation of a micro(bio)sensor array chip for multiple parallel measurements of important cell biomarkers (Q38943574) (← links)
• Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of HepG2 cells and cryopreserved primary human hepatocytes (Q39067234) (← links)
• A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. (Q39089080) (← links)
• In vitro exploration of potential mechanisms of toxicity of the human hepatotoxic drug fenclozic acid. (Q39162099) (← links)
• Microfabricated glucose biosensor for culture well operation. (Q39221228) (← links)
• Bioactivation of the cannabinoid receptor antagonist rimonabant to a cytotoxic iminium ion metabolite. (Q39227319) (← links)
• The gasotransmitter hydrogen sulfide induces nrf2-target genes by inactivating the keap1 ubiquitin ligase substrate adaptor through formation of a disulfide bond between cys-226 and cys-613. (Q39245992) (← links)
• Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification (Q39282645) (← links)
• Characterization of THLE-cytochrome P450 (P450) cell lines: gene expression background and relationship to P450-enzyme activity. (Q39304436) (← links)
• In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. (Q39339881) (← links)
• In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. (Q39464394) (← links)
• HPLC-MS/MS methods for the quantitative analysis of 5-oxoproline (pyroglutamate) in rat plasma and hepatic cell line culture medium (Q39507355) (← links)
• HPLC-MS/MS methods for the quantitative analysis of ophthalmic acid in rodent plasma and hepatic cell line culture medium (Q39617356) (← links)
• Quantification of Drug-Induced Inhibition of Canalicular Cholyl-l-Lysyl-Fluorescein Excretion From Hepatocytes by High Content Cell Imaging (Q40684311) (← links)
• Hepatic effects of repeated oral administration of diclofenac to hepatic cytochrome P450 reductase null (HRN™) and wild-type mice (Q42702145) (← links)
• Recommendations to qualify biomarker candidates of drug-induced liver injury (Q43021434) (← links)
• Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury (Q43244850) (← links)
• Evaluation of the pharmacokinetics, biotransformation and hepatic transporter effects of troglitazone in mice with humanized livers (Q44160577) (← links)
• Evidence of impaired antigen non-specific but normal antigen specific suppressor cell function in children with autoimmune chronic active hepatitis. (Q44491755) (← links)
• Multiscale modelling approach combining a kinetic model of glutathione metabolism with PBPK models of paracetamol and the potential glutathione-depletion biomarkers ophthalmic acid and 5-oxoproline in humans and rats (Q44731939) (← links)
• Glutathione metabolism modeling: a mechanism for liver drug-robustness and a new biomarker strategy (Q44875443) (← links)
• Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity (Q44880285) (← links)
• Functional and toxicological consequences of metabolic bioactivation of methapyrilene via thiophene S-oxidation: Induction of cell defence, apoptosis and hepatic necrosis. (Q45970919) (← links)
• An international network (PlaNet) to evaluate a human placental testing platform for chemicals safety testing in pregnancy. (Q46529441) (← links)
• Identification of the thiophene ring of methapyrilene as a novel bioactivation-dependent hepatic toxicophore. (Q46616054) (← links)
• A mathematical modelling approach to assessing the reliability of biomarkers of glutathione metabolism (Q51535160) (← links)
• A new twist to an old tale: novel insights into the differential toxicities of acetaminophen and its regioisomer N-acetyl-meta-aminophenol (AMAP). (Q51756765) (← links)
• Current Concepts in Drug-Induced Bile Salt Export Pump (BSEP) Interference. (Q53085844) (← links)
• Activation of Flucloxacillin-Specific CD8+ T-Cells With the Potential to Promote Hepatocyte Cytotoxicity in a Mouse Model. (Q53223990) (← links)
• Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development (Q82444022) (← links)
• Do e-cigarettes pose a risk to human health? (Q87053891) (← links)
• Advancing nonclinical innovation and safety in pharmaceutical testing (Q93370113) (← links)